Kopran Ltd

Kopran Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 07 April 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 19 April 2026, providing investors with an up-to-date view of the company's fundamentals, returns, and market performance.

Kopran Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Strong Sell to Sell as of 7 April 2026. This change follows a nuanced shift in technical indicators amid persistent financial headwinds, signalling a cautiously improved outlook despite ongoing operational challenges.

Kopran Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has exhibited a notable shift in its technical momentum, moving from a strongly bearish stance to a mildly bearish trend. Despite a robust day change of 7.43%, the company’s technical indicators present a complex picture, with mixed signals from MACD, RSI, Bollinger Bands, and moving averages, reflecting cautious optimism amid ongoing market challenges.

Kopran Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 25 February 2026. However, the analysis and financial metrics presented here reflect the stock’s current position as of 01 April 2026, providing investors with the latest insights into the company’s performance and outlook.

For the second consecutive session, Kopran Ltd closed lower, slipping to a fresh 52-week low of Rs 109.05 on 30 Mar 2026, marking a 3.92% intraday decline and extending its recent downward momentum to over 10% in just two days.

For the fifth consecutive session, Kopran Ltd closed lower, hitting a fresh 52-week low of Rs 111 on 23 Mar 2026. This decline comes amid a broader market sell-off, but the stock’s underperformance is notably sharper than its sector peers and the benchmark indices.

Kopran Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 25 February 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 21 March 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook.

Kopran Ltd’s shares declined to a fresh 52-week low of Rs.112.1 today, marking a significant milestone in the stock’s ongoing downward trajectory. The pharmaceutical company’s stock has underperformed both its sector and the broader market, reflecting a series of financial setbacks and subdued performance metrics over recent quarters.

Kopran Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, recorded a fresh 52-week low of Rs.115.65 today, marking a significant decline amid a sustained downward trend. The stock has underperformed its sector and broader market indices, reflecting ongoing pressures on its financial performance and valuation metrics.

Kopran Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 25 February 2026. However, the analysis and financial metrics discussed below reflect the stock’s current position as of 10 March 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Kopran Ltd’s shares declined to a fresh 52-week low of Rs.115.75 on 9 Mar 2026, marking a significant milestone in the stock’s ongoing downward trajectory. The pharmaceutical company’s stock has underperformed both its sector and the broader market, reflecting persistent challenges in financial performance and market sentiment.

Kopran Ltd, a key player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, with recent indicators signalling a transition from mildly bearish to a more pronounced bearish trend. Despite some mildly bullish signals on weekly MACD and KST, the overall technical landscape remains challenging, reflecting in the company’s downgraded Mojo Grade to Strong Sell and a significant price decline in early March 2026.

Kopran Ltd, a Pharmaceuticals & Biotechnology micro-cap, has exhibited a nuanced shift in technical momentum as recent data reveals a transition from a strongly bearish stance to a mildly bearish trend. Despite a modest 2.5% gain in the latest session, the company’s technical indicators present a mixed picture, underscoring the challenges faced in reversing longer-term downtrends amid sectoral headwinds and broader market dynamics.

Kopran Ltd, a player in the Pharmaceuticals & Biotechnology sector, has been downgraded from a Sell to a Strong Sell rating by MarketsMOJO as of 25 Feb 2026. This revision reflects deteriorating financial performance, bearish technical indicators, and subdued valuation metrics, signalling heightened caution for investors amid ongoing challenges.

Kopran Ltd, a key player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, with recent indicators signalling a transition from mildly bearish to a more pronounced bearish trend. Despite a modest day gain of 0.86%, the stock’s broader technical landscape and fundamental metrics suggest caution for investors amid sector headwinds and underperformance relative to the Sensex.

Kopran Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 04 February 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 16 February 2026, providing investors with the latest insights into its performance and outlook.